AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00240305
- Locations
- 🇦🇺
Research Site, Perth, Western Australia, Australia
Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia
Phase 4
Withdrawn
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1175
- Registration Number
- NCT00240357
- Locations
- 🇩🇰
Research Site, Ålestrup, Denmark
Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2650
- Registration Number
- NCT00240344
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2776
- Registration Number
- NCT00240331
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00240253
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT00240279
- Locations
- 🇳🇱
Research Site, Nieuwegein, Netherlands
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00240318
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00240292
- Locations
- 🇦🇺
Research Site, Perth, Western Australia, Australia
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00240266
- Locations
- 🇦🇺
Research Site, Melbourne, Victoria, Australia
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00239291
- Locations
- 🇫🇮
Research site, Helsinki, Finland
© Copyright 2024. All Rights Reserved by MedPath